Nanomedicine Tumor Targeting

Area of Science:

• Oncology
• Nanotechnology
• Drug Delivery

Background:

• Nanomedicines are investigated for cancer therapy to improve drug delivery efficiency to tumors and minimize accumulation in healthy tissues.
• Over 20 nanomedicine formulations are approved for cancer treatment, with hundreds more in development, highlighting significant progress in the field.
• Despite advancements, challenges in nanomedicine tumor targeting and clinical translation persist, including material, production, biological barriers, and pathophysiological heterogeneity.

Purpose of the Study:

• To review the principles, progress, and products in nanomedicine for tumor targeting.
• To identify and discuss critical problems and challenges hindering nanomedicine translation.
• To explore future prospects for enhancing the clinical impact of nanomedicines in cancer therapy.

Main Methods:

• Literature review and synthesis of current knowledge on nanomedicine for cancer therapy.
• Analysis of existing nanomedicine products and their clinical translation status.
• Discussion of biological barriers and pathophysiological factors affecting nanomedicine efficacy.

Main Results:

• Nanomedicines offer improved efficacy and reduced toxicity in cancer treatment through targeted delivery.
• Key bottlenecks in nanomedicine translation include biological barriers and tumor heterogeneity, extending beyond material science.
• Numerous nanomedicine formulations show promise, but clinical impact is limited by unresolved challenges.

Conclusions:

• Nanomedicine holds significant potential for cancer therapy by optimizing drug delivery and safety profiles.
• Addressing biological barriers and tumor heterogeneity is crucial for successful clinical translation of nanomedicines.
• Future research should focus on overcoming current challenges to maximize the clinical benefits of nanomedicine in oncology.